The CHAMP study will tell us if immiquimod can clear high risk strains of the human papillomavirus (HPV) among HIV+ men who have sex with men (MSM) and how tolerable the treatment might be.
This is important as HIV+ men have a much higher incidence of anal cancer (which can be caused by certain high risk HPV strains).
Who can join the study?
People assigned male at birth and who still identify as male, can join the study if they are:
Aged 18 and over
Have not had anal cancer in the preceding 12 months.
Ethics and confidentiality
This study has been approved by the Alfred Hospital Ethics Committee (473/17). Your personal details and any information obtained in connection with this study will remain confidential and will only be used for the purpose of this research project.
The IMPRESS study:
Males aged 17-19 are invited to join this research project:, “Prevalence of genital HPV infection in males following introduction of universal male Human Papillomavirus (HPV) vaccination”.
Human Papillomavirus (HPV) is a very common sexually transmitted virus that can lead to HPV-related cancers and disease in males and females. Different types of HPV can affect different parts of the body, and some types are more harmful than others. HPV can cause genital warts, which can be distressing but do not cause cancer.
This research project aims to demonstrate a fall in HPV infection in teenage males as a result of the introduction of a male vaccination program in Australia. There is already a female vaccination program in place in Australia which has resulted in a fall in HPV infection in females.
Nore about the study
- Send an SMS to the above number
- Ask your clinician about IMPRESS when you are next at MSHC